Cronos Group Inc (CRON)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.24B
Last updated: Nov 17, 2026 at 11:04 AM ET
Cronos Group Inc (CRON) P/E Ratio & Valuation History
Cronos Group (CRON) trades at 28.4x trailing earnings and 5.6x sales. Its P/S of 5.6x is below its 5-year median of 8.7x. Its forward P/E is 22.8x. The median P/E across 10 similar companies is 10.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 24.6% higher over the next year. Its free cash flow yield is 5.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 28.4x |
| Forward P/E | 22.8x |
| Price to sales | 5.6x |
| Price to book | 1.1x |
| EV/EBITDA | 20.1x |
| Price to FCF | 18.3x |
| EV/FCF | 12.0x |
| PEG | N/A |
| FCF yield | 5.5% |
Historical Medians
Against its 10-year medians, its P/S is 73.6% below 21.2x and its P/B is in line.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 5.6x | 8.7x | 21.2x |
| P/B | 1.1x | 0.9x | 1.1x |
Valuation History
Over the 3 of the 10 year ends shown that have a P/E, its P/E ranged from 12.7x in 2024 to 191.8x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $2.63 | 104.0x | 6.9x | 0.9x |
| 2024 | $2.02 | 12.7x | 6.6x | 0.7x |
| 2023 | $2.09 | N/A | 9.1x | 0.7x |
| 2022 | $2.54 | N/A | 11.1x | 0.8x |
| 2021 | $3.92 | N/A | 22.5x | 1.1x |
| 2020 | $6.94 | N/A | 44.8x | 1.4x |
| 2019 | $7.67 | 191.8x | 106.4x | 2.2x |
| 2018 | $10.39 | N/A | 162.3x | 9.1x |
| 2017 | $7.73 | N/A | 293.0x | 15.2x |
| 2016 | $1.10 | N/A | N/A | 2.8x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CRON
What is CRON's forward P/E ratio?
Cronos Group has a forward P/E ratio of 22.8x.
Is CRON stock overvalued?
GNG's valuation label for CRON is Undervalued. Its P/E of 28.4x compares with a median of 10.5x across 10 similar companies.
What is CRON's price to sales ratio?
Cronos Group has a price to sales ratio of 5.6x.
CRON pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors